Dinoprostone vaginal insert - Ferring Pharmaceuticals

Drug Profile

Dinoprostone vaginal insert - Ferring Pharmaceuticals

Alternative Names: Cervidil; FE 999901; FE 999901 vaginal insert; Propess

Latest Information Update: 24 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Abortifacients; Oxytocics; Prostaglandins
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Labour induction

Most Recent Events

  • 03 Apr 2017 Ferring Pharmaceutical initiates enrolment in a phase III trial for Labour induction in Japan (NCT03067727)
  • 21 Mar 2017 Launched for Labour induction in New Zealand, Italy, Canada, Australia, Poland, Hong Kong, Czech Republic, Hungary, Finland, Ireland, China, South Africa, Greece, Turkey, Switzerland, Sweden, Spain, Portugal, Netherlands, Mexico, Israel, Germany, France, Denmark, Belgium, Austria, Argentina, Brazil and United Kingdom before March 2017 (Vaginal)
  • 17 Mar 2017 Ferring Pharmaceutical plans a phase III trial for Labour induction in Japan (NCT03067727)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top